Recent Quotes (30 days)

You have no recent quotes
chg | %

Concordia International Corp  

(Public, TSE:CXR)   Watch this stock  
Find more results for CXR
-0.02 (-0.39%)
Delayed:   12:59PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 5.10 - 5.34
52 week 4.52 - 28.35
Open 5.10
Vol / Avg. 286,011.00/1.19M
Mkt cap 239.28M
P/E     -
Div/yield     -
EPS -16.17
Shares 51.02M
Beta -2.63
Inst. own     -
Nov 10, 2016
Q3 2016 Concordia International Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 12, 2016
Q2 2016 Concordia International Corp Earnings Release
Aug 12, 2016
Q2 2016 Concordia International Corp Earnings Call - Webcast

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -246.16% -7.46%
Operating margin -219.02% 20.41%
EBITD margin - 54.41%
Return on average assets -47.93% -1.00%
Return on average equity -314.82% -4.16%
Employees 214 -
CDP Score - -


277 Lakeshore Rd E Suite 302
+1-905-8425150 (Phone)
+1-905-8425154 (Fax)

Website links


Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Officers and directors

Mark L. Thompson Chairman of the Board, Chief Executive Officer, Founder
Age: 47
Wayne Kreppner President, Chief Operating Officer
Age: 41
Edward J. Borkowski CPA Chief Financial Officer
Age: 58
Robert Altman Ph.D. President - Pinnacle Biologics Inc.
Age: 62
Arijit Mookerjee Managing Director, Chief Financial Officer - Operations
Leith Tessy Treasurer, Secretary
Age: 52
Jordan M. Kupinsky J.D. Lead Independent Director
Age: 42
Patrick Vink M.D. Director
Age: 51
Douglas N. Deeth Independent Director
Age: 67
Rochelle Fuhrmann Independent Director
Age: 45